Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection

We report the first case of a patient with hepatitis C virus (HCV) infection and idiopathic thrombocytopenic purpura (ITP), who later developed acquired amegakaryocytic thrombocytopenia (AAMT), with autoantibodies to the thrombopoietin (TPO) receptor (c-Mpl). A 64-year-old woman, with chronic hepatitis C, developed severe thrombocytopenia and was diagnosed with ITP. She died of liver failure. Autopsy revealed cirrhosis and liver carcinoma. In the bone marrow, a marked reduction in the number of megakaryocytes was observed, while other cell lineages were preserved. Therefore, she was diagnosed with AAMT. Additionally, autoantibodies to c-Mpl were detected in her serum. Autoantibodies to c-Mpl are one of the causes of AAMT, acting through inhibition of TPO function, megakaryocytic maturation, and platelet formation. HCV infection induces several autoantibodies. HCV infection might also induce autoantibodies to c-Mpl, resulting in the development of AAMT. This mechanism may be one of the causes of thrombocytopenia in patients with HCV infection.

[1]  F. Azzaroli,et al.  Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature. , 2015, World journal of hepatology.

[2]  Y. Maehara,et al.  Management of thrombocytopenia due to liver cirrhosis: a review. , 2014, World journal of gastroenterology.

[3]  K. Katsanos,et al.  Platelet IgG antibodies are significantly increased in chronic liver disease , 2011, Annals of gastroenterology.

[4]  B. B. Weksler Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease , 2007, Alimentary pharmacology & therapeutics.

[5]  Stefan Sleijfer,et al.  Side Effects of Interferon-α Therapy , 2005, Pharmacy World and Science.

[6]  M. Kuwana,et al.  Anti-c-Mpl (thrombopoietin receptor) autoantibody-induced amegakaryocytic thrombocytopenia in a patient with systemic sclerosis. , 2003, Arthritis and rheumatism.

[7]  Y. Ikeda,et al.  Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. , 2002, Arthritis and rheumatism.

[8]  V. Broudy,et al.  Human platelets display high-affinity receptors for thrombopoietin. , 1997, Blood.

[9]  R. Hoffman,et al.  An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. , 1985, The New England journal of medicine.

[10]  P. P.,et al.  Acquired amegakaryocytic thrombocytopenic purpura. , 2016, The Journal of the Association of Physicians of India.

[11]  S. Sleijfer,et al.  Side effects of interferon-alpha therapy. , 2005, Pharmacy world & science : PWS.

[12]  M. Ballmaier,et al.  c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. , 2001, Blood.